First Tracks Biotherapeutics Reports Q3 GAAP EPS of -$0.88, Beating Estimates
First Tracks Biotherapeutics (TRAX) has reported its third-quarter financial results, posting a GAAP earnings per share (EPS) of -$0.88. This figure slightly outperformed market expectations by $0.03. The company maintains a strong liquidity position with cash and cash equivalents totaling $155.63 million. Recent strategic developments include a $200 million private placement and ongoing clinical focus on its ANB033 candidate, which continues to be a central driver of the company's research and development efforts.
Tickers: $TRAX
Topics: cash position earnings beat GAAP EPS